Breaking News Instant updates and real-time market news.

SHPG

Shire

$147.37

2.74 (1.89%)

, RHHBY

Roche

$29.10

0.205 (0.71%)

15:32
11/20/17
11/20
15:32
11/20/17
15:32

Shire selloff on Roche news seems overdone, says BTIG

BTIG analyst Timothy Chiang said today's weakness in Shire (SHPG) shares is overdone and creates a potential buying opportunity. While Roche's (RHBBY) emicizumab is likely to gain share at the expense of Shire's Advate, he does not expect a rapid conversion and thinks Shire's pipeline and platform seem overly discounted at current levels. Chiang has a Buy rating and $242 price target on Shire shares.

SHPG

Shire

$147.37

2.74 (1.89%)

RHHBY

Roche

$29.10

0.205 (0.71%)

  • 30

    Nov

  • 23

    Dec

  • 23

    Feb

SHPG Shire
$147.37

2.74 (1.89%)

11/16/17
CANT
11/16/17
NO CHANGE
Target $222
CANT
Overweight
Roche's black box warning positive for Shire, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen says the black box warning put on Roche's (RHHBY) Hemlibra by the FDA is a positive for Shire (SHPGY). The analyst believes the news supports her belief that concerns about competition for Shire's hemophilia franchise are overdone. Chen keeps an Overweight rating on Shire with a $222 price target. The stock in afternoon trading is up 4% to $146.13.
11/16/17
RBCM
11/16/17
NO CHANGE
RBCM
Top Pick
Roche approval neutral to slightly negative for Shire, says RBC Capital
RBC Capital analyst Douglas Miehm views the FDA approval for Roche's (RHHBY) Hemlibra as neutral to slight negative for Shire (SHPG). The approval comes three months early while the labeling for the hemophilia A drug contains a black box warning that severe blood clots may occur when Hemlibra is used with Feiba, Miehm tells investors in a research note. He believes investors will be "somewhat surprised" by the early timing of the approval but not surprised by the black box warning. He notes his estimates for Shire already reflect a 73% decline in inhibitor revenue from 2017 through 2025. Miehm keeps an Outperform rating on Shire. The stock in afternoon trading is up 5% to $146.66. Bioverativ (BIVV), another company with a hemophilia A treatment, is up 2% to $56.45.
11/15/17
SUSQ
11/15/17
NO CHANGE
Target $225
SUSQ
Positive
Shire outlook remains underappreciated, says Susquehanna
Susquehanna analyst Andrew Finkelstein believes the outlook for Shire remain underappreciated. The analyst said the shares are trading at a low valuation and the company is well positioned for growth despite headwinds that are common across the sector. He sees growth accelerating and multiple levers to extend that runway. Finkelstein reiterated his Positive rating and $225 price target on Shire shares.
11/14/17
11/14/17
UPGRADE

Shire upgraded to Buy from Hold at Liberum
Liberum analyst Roger Franklin upgraded Shire to Buy with a price target of GBP 42.
RHHBY Roche
$29.10

0.205 (0.71%)

11/20/17
PIPR
11/20/17
NO CHANGE
Target $71
PIPR
Overweight
Piper a buyer of Bioverativ on Roche study selloff
Piper Jaffray analyst Christopher Raymond says he remains a buyer of Bioverativ (BIVV) after Roche (RHHBY) announced that its Haven 3 Phase III study met its primary endpoint. The analyst is waiting for the full data, expected in May, regarding absolute annualized bleed rates and consistency of effect. He remains confident in his forward estimates for Bioverativ's Eloctate and keeps an Overweight rating on the shares with a $71 price target. Absent full data detailing absolute annualized bleed rates for Roche's Hemlibra, it's difficult to draw too many conclusions on the relative efficacy compared to Eloctate in the non-inhibitor population, Raymond tells investors in a research note.
11/16/17
JEFF
11/16/17
NO CHANGE
JEFF
Buy
Jefferies names Roche new top global pick in Pharmaceuticals
Jefferies analyst Jeffrey Holford names Roche (RHHBY) his new "Top Pick Globally" in Pharmaceuticals following the strong share performance of his previous top pick for 2017, AbbVie (ABBV). The analyst believes the company's growth outlook is better than many investors think. Roche is nearing sentiment lows and investors "need to look hard at the replacement power" offered by assets Tecentriq, Ocrevus, Gazyva, ACE910 and Perjeta, Holford tells investors in a research note. Following Roche, the analyst has the highest conviction on Novartis (NVS), Bayer (BAYRY), AbbVie, Johnson & Johnson (JNJ), Zoetis (ZTS) and Eli Lilly (LLY). His least preferred stocks in Pharmaceuticals are Merck (MRK), Novo Nordisk (NVO) and AstraZeneca (AZN).

TODAY'S FREE FLY STORIES

CTLT

Catalent

$39.54

-0.2 (-0.50%)

08:00
12/13/17
12/13
08:00
12/13/17
08:00
Initiation
Catalent initiated  »

Catalent initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:00
12/13/17
12/13
08:00
12/13/17
08:00
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

TSM

TSMC

$39.30

-0.07 (-0.18%)

07:57
12/13/17
12/13
07:57
12/13/17
07:57
Periodicals
TSMC chairman says HPC chip demand remains strong, DigiTimes reports »

TSMC (TSM) chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KR

Kroger

$26.33

-0.25 (-0.94%)

07:56
12/13/17
12/13
07:56
12/13/17
07:56
Conference/Events
Kroger management to meet with Deutsche Bank »

Field trip to company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

ST

Sensata

$51.66

3.76 (7.85%)

07:55
12/13/17
12/13
07:55
12/13/17
07:55
Recommendations
Sensata analyst commentary  »

Sensata price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$15.70

-0.17 (-1.07%)

, FTR

Frontier Communications

$10.05

-0.01 (-0.10%)

07:55
12/13/17
12/13
07:55
12/13/17
07:55
Recommendations
CenturyLink, Frontier Communications, Windstream analyst commentary  »

Morgan Stanley says…

CTL

CenturyLink

$15.70

-0.17 (-1.07%)

FTR

Frontier Communications

$10.05

-0.01 (-0.10%)

WIN

Windstream

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNM

Unum Group

$56.40

-0.25 (-0.44%)

07:55
12/13/17
12/13
07:55
12/13/17
07:55
Conference/Events
Unum Group to host investor day »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HON

Honeywell

$153.74

0.53 (0.35%)

07:55
12/13/17
12/13
07:55
12/13/17
07:55
Conference/Events
Honeywell to hold a conference call »

Management provides 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

JLL

Jones Lang LaSalle

$149.76

0.56 (0.38%)

07:55
12/13/17
12/13
07:55
12/13/17
07:55
Conference/Events
Jones Lang LaSalle to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

AAPL

Apple

$171.70

-0.97 (-0.56%)

07:52
12/13/17
12/13
07:52
12/13/17
07:52
Periodicals
Apple hires Matthys, Grazier for business affairs on content team, Variety says »

Apple has hired Philip…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMTD

TD Ameritrade

$52.69

0.61 (1.17%)

07:51
12/13/17
12/13
07:51
12/13/17
07:51
Syndicate
TD Ameritrade 27.7M share Spot Secondary priced at $51.50 »

Goldman Sachs acted as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUBS

HubSpot

$82.70

-0.7 (-0.84%)

07:50
12/13/17
12/13
07:50
12/13/17
07:50
Conference/Events
HubSpot management to meet with Needham »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 15

    Dec

VZ

Verizon

$53.19

1.35 (2.60%)

07:50
12/13/17
12/13
07:50
12/13/17
07:50
Conference/Events
Verizon management to meet with Deutsche Bank »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CRL

Charles River

$104.57

0.67 (0.64%)

07:50
12/13/17
12/13
07:50
12/13/17
07:50
Initiation
Charles River initiated  »

Charles River initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAY

Verifone

$18.47

0.28 (1.54%)

07:50
12/13/17
12/13
07:50
12/13/17
07:50
Technical Analysis
Technical View: Verifone falls after earnings and outlook disappoint »

In premarket trading the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

FRED

Fred's

$3.77

-0.19 (-4.80%)

07:49
12/13/17
12/13
07:49
12/13/17
07:49
Conference/Events
Fred's management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

NICE

Nice

$87.71

0.03 (0.03%)

07:47
12/13/17
12/13
07:47
12/13/17
07:47
Recommendations
Nice analyst commentary  »

Nice price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

PM

Philip Morris

$107.30

1.26 (1.19%)

07:46
12/13/17
12/13
07:46
12/13/17
07:46
Recommendations
Philip Morris analyst commentary  »

Philip Morris named a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXL

Hexcel

$60.98

1.64 (2.76%)

07:45
12/13/17
12/13
07:45
12/13/17
07:45
Recommendations
Hexcel analyst commentary  »

Hexcel investor day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$73.62

0.33 (0.45%)

, VNTV

Vantiv

$74.79

0.17 (0.23%)

07:42
12/13/17
12/13
07:42
12/13/17
07:42
Recommendations
PayPal, Vantiv, ADP, Paychex, Amazon.com analyst commentary  »

Wedbush bullish on…

PYPL

PayPal

$73.62

0.33 (0.45%)

VNTV

Vantiv

$74.79

0.17 (0.23%)

ADP

ADP

$117.05

-0.77 (-0.65%)

PAYX

Paychex

$68.71

-0.31 (-0.45%)

AMZN

Amazon.com

$1,165.08

-3.84 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 21

    Dec

  • 08

    Jan

  • 18

    Mar

AEE

Ameren

$61.36

-1.8425 (-2.92%)

07:42
12/13/17
12/13
07:42
12/13/17
07:42
Downgrade
Ameren rating change  »

Ameren cut to Underweight…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$171.70

-0.97 (-0.56%)

07:41
12/13/17
12/13
07:41
12/13/17
07:41
Periodicals
Apple SVP Phil Schiller talks Face ID, HomePod delay, T3 reports »

Apple SVP of worldwide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$190.95

-10.85 (-5.38%)

07:41
12/13/17
12/13
07:41
12/13/17
07:41
Downgrade
bluebird bio rating change  »

bluebird bio downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

PRLB

Proto Labs

$95.85

1.85 (1.97%)

07:40
12/13/17
12/13
07:40
12/13/17
07:40
Earnings
Proto Labs guides initial FY18 EPS $2.40-$2.60, consensus $2.51 »

Guides initial FY18…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRN

Trinity Industries

$36.88

1.08 (3.02%)

07:39
12/13/17
12/13
07:39
12/13/17
07:39
Recommendations
Trinity Industries analyst commentary  »

Trinity Industries price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.